| Theme |
Perspective for Chemotherapy in Gastrointestinal Malignancy Based on Current Evidence |
| Title |
Chemotherapy for Advanced Gastric Cancer |
| Author |
Yoshihiro Shibata |
Department of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital |
| Author |
Hitoshi Kusaba |
Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University |
| Author |
Eishi Baba |
Department of Comprehensive Clinical Oncology, Graduate School of Medical Sciences, Kyushu University |
| [ Summary ] |
Standard chemotherapeutic regimens for advanced gastric cancer (AGC) have been established through many randomized controlled trials. In Japanese studies, the efficacy of S-1 agents as compared to the previous standard 5-FU and the superiority of S-1 plus cisplatin over the single agent S-1, were demonstrated for AGC therapy. Thus, S-1 plus cisplatin is considered to be the standard first-line regimen in Japan. The other S-1-based doublet therapies including S-1 plus irinotecan and S-1 plus docetaxel were not shown to be superior to S-1. Recently, paclitaxel (PTX) has been reported to be useful as a second line treatment. PTX has also been suggested as a promising therapy for AGC with peritoneal dissemination. Since many clinical studies are ongoing, the development of new therapeutic strategies is expected |